Search clinical trials for: β-thalassemia

Total 20 results

Shenzhen Hemogen

Recruiting

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia

β-thalassemia

China
Shanghai BDgene Co., Ltd.
Ruijin Hospital

Not yet recruiting

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia

β-thalassemia

China
Shanghai BDgene Co., Ltd.
Shanghai Children's Medical Center

Not yet recruiting

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia

β-thalassemia
Shenzhen Hemogen

Recruiting

Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

β-thalassemia

China
Shanghai BDgene Co., Ltd.
920th Hospital of Joint Logistics Support Force of People's Liberation Army...

Recruiting

A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants

Hematologic Diseases

China
BGI-research
Shenzhen Children's Hospital

Not yet recruiting

Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

β-Thalassemia Major

China
Bioray Laboratories
PLA 923 Hospital

Terminated

β-globin Restored Autologous HSC in β-thalassemia Major Patients

β-thalassemia Major

China
Prothya Biosolutions

Terminated

Apotransferrin in Patients With β-thalassemia

β-thalassemia Intermedia

Netherlands
Protagonist Therapeutics, Inc.

Completed

Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia (TRANSCEND)

Chronic Anemia | β-thalassemia | Ineffective Erythropoiesis

United States, Malaysia, Turkey, Thailand, United Kingdom, Italy, Lebanon, Tunisia, Greece
Protagonist Therapeutics, Inc.

Completed

Safety Study for Beta Thalassemia Subjects on PTG-300 (TRANSCEND)

β-thalassemia | Ineffective Erythropoiesis

Malaysia, Thailand, United States, Greece, United Kingdom, Turkey, Lebanon, Tunisia
Novartis Pharmaceuticals

Completed

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

Transfusional Iron Overload | β-thalassemia

Italy
bluebird bio

Completed

A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants

β-thalassemia Major

United States, Australia, Thailand
Assiut University

Unknown

Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox

β-thalassemia

Egypt
Novartis Pharmaceuticals

Withdrawn

An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old (MACS2163)

β-thalassemia Major
Novartis Pharmaceuticals

Completed

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

Transfusional Iron Overload | β-thalassemia Major | Pediatric Rare Anemia

Italy, France
Columbia University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Fresh Versus Old Red Blood Cells for Transfusion

Iron, Abnormal Blood Level | Other Abnormal Blood Chemistry

United States
Aghia Sophia Children's Hospital of Athens

Unknown

B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals

Asplenia | β-thalassemia Major

Greece
Novartis Pharmaceuticals

Completed

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

Transfusional Iron Overload in β-thalassemia

United States, Greece, Argentina, Germany, Belgium, Italy, United Kingdom, France, Tunisia, Canada, Turkey, Brazil
Novartis Pharmaceuticals

Completed

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

Anemia | Hemosiderosis

United States, Germany, Belgium, United Kingdom, Italy, Canada, France
Shiraz University of Medical Sciences

Completed

Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia

β-Thalassemia Intermedia

Iran, Islamic Republic of

3

Subscribe